p21 antibody

Catalog No. ABIN105216

Product Details anti-p21 Antibody

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This p21 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Characteristics: Concentration Definition: by UV absorbance at 280 nm

Immunogen: This protein A purified monoclonal antibody was produced by repeated immunizations with recombinant human p21 fusion protein.
Immunogentype:Recombinant

Clone: WA-1

Isotype: IgG

Application Details

Application Notes: This antibody is suitable for immunohistochemistry, ELISA and immunoblotting. The antibody detects a 21 kDa band corresponding to the p21 protein.  MCF7 cells or UV treated fibroblasts are suggested as a positive control for immunoblotting and immunohistochemistry.   Methanol/acetone fixed tissue is reactive for immunohistochemistry. The antibody also reacts with breast carcinoma on frozen sections (methanol/acetone fixation) and on paraffin sections (formalin fixation and microwave treatment prior to staining).  In ELISA this monoclonal antibody is useful either as a capture antibody (attached to the solid phase) or for detection of p21 protein.  This antibody immunoprecipitates monomeric p21WAF1 and not p21 complexes with other proteins. High level expression of p21WAF1 requires induction of wild-type p53 expression (e.g. via exposure to DNA damaging agents).

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.0 mg/mL

Buffer: 0.02 M Potassium Phosphate, 0.5 M Sodium Chloride, pH 7.2

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

References for anti-p21 antibody (ABIN105216)

Supiot, Hill, Bristow: "Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53." in: Molecular cancer therapeutics, Vol. 7, Issue 4, pp. 993-9, (2008) (PubMed).

Joshi, Chen, Kalemkerian, Adil, Kraut, Sarkar: "Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer." in: Cancer gene therapy, Vol. 5, Issue 3, pp. 183-91, (1998) (PubMed).

Kagawa, Fujiwara, Hizuta, Yasuda, Zhang, Roth, Tanaka: "p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells." in: Oncogene, Vol. 15, Issue 16, pp. 1903-9, (1997) (PubMed).

Yang, Perkins, Ohno, Nabel, Nabel: "The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo." in: Nature medicine, Vol. 1, Issue 10, pp. 1052-6, (1996) (PubMed).

Waldman, Kinzler, Vogelstein: "p21 is necessary for the p53-mediated G1 arrest in human cancer cells." in: Cancer research, Vol. 55, Issue 22, pp. 5187-90, (1995) (PubMed).

Yeh, Shatkin: "A cis-acting element in Rous sarcoma virus long terminal repeat required for promoter repression by HeLa nuclear protein p21." in: The Journal of biological chemistry, Vol. 270, Issue 26, pp. 15815-20, (1995) (PubMed).

Target Details for p21

Target: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Alternative Name: p21 WAF1 (CDKN1A Products)

Synonyms: CCND1 antibody, CDKN1A antibody, CAP20 antibody, CDKN1 antibody, CIP1 antibody, MDA-6 antibody, P21 antibody, SDI1 antibody, WAF1 antibody, p21CIP1 antibody, CDKI antibody, Cdkn1 antibody, Waf1 antibody, mda6 antibody, p21Cip1 antibody, p21WAF antibody, Cip1 antibody, UV96 antibody, p21 antibody, cip1 antibody, p16Xic2 antibody, sdi1 antibody, waf1 antibody, cap20 antibody, cdkn1 antibody, mda-6 antibody, p21cip1 antibody, si:ch1073-48m5.2 antibody, KRAS2 antibody, p21ras antibody, cyclin D1 antibody, cyclin dependent kinase inhibitor 1A antibody, cyclin-dependent kinase inhibitor 1A (P21) antibody, cyclin-dependent kinase inhibitor 1A antibody, cyclin-dependent kinase inhibitor 1A L homeolog antibody, cyclin-dependent kinase inhibitor 1 antibody, KRAS proto-oncogene, GTPase antibody, CCND1 antibody, CDKN1A antibody, Cdkn1a antibody, cdkn1a.L antibody, cki1 antibody, cdkn1a antibody, KRAS antibody

Background: P21WAF1 is a tumor suppressor gene product critical to maintain proper regulatory control of cell division.  p21WAF1 inhibits cyclin/cyclin-dependent kinase (cdk) complexes, causing cell cycle arrest by blocking cell division at the S phase. Various mutations of tumor suppressor genes have been associated with different types of cancers.  In these cases, somatic gene therapy with wild-type versions of tumor suppressor genes have been contemplated as anti-cancer therapeutic approaches.  p21WAF1 contains p53-binding sites in its promoter and expression of p21WAF1 is induced in WI38 fibroblasts with PMA. The induction of and
Synonyms: Cyclin-dependent kinase inhibitor 1A (p21, Cip1) antibody, DNA Synthesis Inhibitor antibody, MDA 6 antibody, MDA6 antibody, Melanoma Differentiation Associated Protein 6 antibody

Gene ID: 1026

NCBI Accession: NP_510867

UniProt: P38936

Pathways: p53 Signaling, PI3K-Akt Signaling, Cell Division Cycle, AMPK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagy